C12Y304/21026

ROTHIA SUBTILISINS, S8A FAMILY PROTEASES, AS THERAPEUTIC ENZYMES FOR APPLICATION IN GLUTEN-INTOLERANCE DISORDERS

There are gluten-degrading enzymes found in Rothia species bacteria that are subtilisins that belonging to the S8A family of serine protease family. The Rothia sp. derived subtilisin-like enzymes have the conserved catalytic triad composed of a Ser, His, and Asp residues that is characteristic of the serine protease family. The Rothia subtilisin enzymes are potent at cleaving proline-containing proteins, cleaving the second peptide bond after proline in the XPX1 motif, where X is any amino acid, P is proline and X1 is a hydrophobic amino acid, e.g. the XPQ motif, where Q is glutamine. Embodiments herein provide isolated enzyme compositions and formulations comprising subtilisins gluten-degrading enzyme from a Rothia species bacteria. Also provided herein are methods of treatment of celiac disease or a related disorder, treatment of gluten-containing foodstuff, degrading and/or detoxifying gluten comprising the subtilisins gluten-degrading enzyme and/or compositions.

Immobilized Proline-specific endoprotease
10196630 · 2019-02-05 · ·

The present invention relates to immobilized proline-specific endoprotease, wherein the proline-specific endoprotease is immobilized on a carrier comprising methacrylate which has been functionalized with amino dimethylene, and wherein the carrier has a particle size range of 100 to 400 m. The invention also relates to a process for producing beer comprising the steps of preparing a mash, fermenting the beer, and stabilizing the beer, wherein the beer is incubated with the immobilized proline-specific endoprotease.

Treatment for Gastroesophageal Reflux Disease Caused by a Neurological Disorder
20180169158 · 2018-06-21 ·

An embodiment is a method of mitigating or treating Gastroesophageal Reflux Disease (GERD) caused by a neurological disorder that includes administering an effective amount of a medicament that includes a supernatant resulting from culturing Lactobacillus bulgaricus B-30892 bacteria to a human to mitigate or treat GERD caused by a neurological disorder.

PROLINE-SPECIFIC ENDOPROTEASE AND USE THEREOF

The present invention relates to a polypeptide having proline-specific endoprotease activity, wherein the polypeptide has less than 70% residual activity when the polypeptide has been kept at a temperature of 65 C. for 15 min.

The invention further relates to a polypeptide having proline-specific endoprotease activity comprising an amino acid sequence according to SEQ ID NO: 1, wherein SEQ ID NO: 1 comprises at least one combination of amino acid substitutions selected from the group consisting of a combination selected from the group consisting of (K238E, I204V, V460A), (F279S, A242V, N507I), (T145A, K424M), (T359A, F379S), (M170I, A421T), (N441S, G484S), (L470H, Q288R), (L470H, E387G), (T281S, L373I), (P304A, P469A), and (P466T, P469Q), a nucleic acid encoding a polypeptide having proline-specific endoprotease activity, a method of making a variant polypeptide having proline-specific endoprotease activity, a recombinant host cell and a method of producing the polypeptide and a process for the preparation of a food or feed product wherein the polypeptide is used.

Use of galerina marginata genes and proteins for peptide production

The present invention relates to compositions and methods comprising genes and peptides associated with cyclic peptides and cyclic peptide production in mushrooms. In particular, the present invention relates to using genes and proteins from Galerina species encoding peptides specifically relating to amatoxins in addition to proteins involved with processing cyclic peptide toxins. In a preferred embodiment, the present invention also relates to methods for making small peptides and small cyclic peptides including peptides similar to amanitin. Further, the present inventions relate to providing kits for making small peptides.

Treatment and prophylaxis for gastroesophageal reflux disease
09925225 · 2018-03-27 · ·

An embodiment is a method of preventing, mitigating or treating Gastroesophageal Reflux Disease (GERD) that includes administering an effective amount of a medicament comprised of the Lactobacillus bulgaricus B-30892 strain and/or bioactive compounds from its supernatant to a human to prevent, mitigate or treat GERD.

Compositions and Methods for Diagnosis and Treatment of Cancer

The present invention relates to the diagnosis and treatment of cancerous diseases, in particular cancerous diseases expressing Seprase (Fap-alpha; fibroblast activation protein alpha). More particularly, the invention concerns peptides targeting Seprase.

Use of an acidic soft drink to enhance the efficacy of a gluten-digesting enzyme

This invention relates to the use of an acidic soft drink for improving the efficiency of gluten digestion and more specifically of a gluten-digesting enzyme supplement. Said use allows maintaining or enhancing gastrointestinal comfort in celiac or non-celiac gluten sensitive individuals, or delaying the onset of gastrointestinal discomfort in non-celiac gluten sensitive healthy individuals using a reduced amount of gluten-digesting enzyme. Furthermore, it relates to an acidic soft drink having a pH in the range of 2 to 3.5 for use to support gluten digestion, and to prevent gastrointestinal discomfort following the ingestion of a gluten-containing meal by a gluten-sensitive consumer.

USE OF GALERINA MARGINATA GENES AND PROTEINS FOR PEPTIDE PRODUCTION

The present invention relates to compositions and methods comprising genes and peptides associated with cyclic peptides and cyclic peptide production in mushrooms. In particular, the present invention relates to using genes and proteins from Galerina species encoding peptides specifically relating to amatoxins in addition to proteins involved with processing cyclic peptide toxins. In a preferred embodiment, the present invention also relates to methods for making small peptides and small cyclic peptides including peptides similar to amanitin. Further, the present inventions relate to providing kits for making small peptides.

PROLINE-SPECIFIC ENDOPROTEASE AND USE THEREOF

The present invention relates to a polypeptide having proline-specific endoprotease activity, wherein the polypeptide has less than 70% residual activity when the polypeptide has been kept at a temperature of 65 C. for 15 min.

The invention further relates to a polypeptide having proline-specific endoprotease activity comprising an amino acid sequence according to SEQ ID NO: 1, wherein SEQ ID NO: 1 comprises at least one amino acid substitution selected from the group consisting of P469A, P469C, P469D, P469E, P469F, P469G, P469H, P469I, P469K, P469L, P469M, P469N, P469Q, P469R, P469S, P469T, P469V, P469W, P469Y, a nucleic acid encoding a polypeptide having proline-specific endoprotease activity, a method of making a variant polypeptide having proline-specific endoprotease activity, a recombinant host cell and a method of producing the polypeptide and a process for the preparation of a food or feed product wherein the polypeptide is used.